Corpus ID: 12588288

Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

  title={Expression of cyclooxygenase-1 and -2 in human colorectal cancer.},
  author={H. Sano and Y. Kawahito and R. Wilder and A. Hashiramoto and S. Mukai and K. Asai and S. Kimura and H. Kato and M. Kondo and T. Hla},
  journal={Cancer research},
  volume={55 17},
Several studies indicate that nonsteroidal anti-inflammatory drugs including indomethacin, aspirin, sulindac, and piroxicam reduce the risk of colon cancer. Furthermore, nonsteroidal anti-inflammatory drugs that inhibit the cyclooxygenase (COX) enzyme were shown to inhibit the development of colon cancer in animal models of carcinogenesis. Non-steroidal anti-inflammatory drugs inhibit the enzymatic activity of both the constitutive (COX-1) and inducible (COX-2) isoforms of COX enzyme. We have… Expand
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.
The results suggest that overexpression of COX may not be unique to colon cancer and may be a feature common to other epithelial tumors. Expand
Expression of cyclooxygenase-2 in human lung carcinoma.
The data suggest that Cox-2 is expressed in human lung carcinomas and in precursor lesions leading to this malignancy. Expand
Cyclooxygenases and colon cancer.
The relationship between COX-2 and colon cancer is further confirmed by studies using the murine models of adenomatous polyposis coli, in which NSAIDs and gene knockouts reduce the number of spontaneously developing intestinal polyps. Expand
Advances in Brief Expression of Cyclooxygenase-2 in Human Lung Carcinoma 1
Interestingly, atypical alveolar epithelium, which associates with asbestosis and idiopathic fibrosing alveolitis and is considered to be a precursor lesion for lung cancer, expressed the Cox-2 protein. Expand
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.
It is demonstrated that constitutive expression of COX-2 can lead to phenotypic changes that alter the metastatic potential of colorectal cancer cells and be reversed by treatment with sulindac sulfide, a known COX inhibitor. Expand
Role of cyclooxygenase-2 in colorectal cancer
Data indicate that COX-2 is involved in the regulation of apoptosis, angiogenesis, and tumor cell invasiveness, which appear to contribute to its effects on tumorigenesis. Expand
Cyclooxygenase (COX)-2 as a potent molecular target for prevention and therapy of oral cancer
It is indicated that COX-2 becomes a potent molecular target for prevention and therapy of oral cancer. Expand
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Evidence is provided that there may be a direct link between inhibition of intestinal cancer growth and selective inhibition of the COX-2 pathway. Expand
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.
It is reported for the first time that the selective COX-1 inhibitor SC-560 exhibits anti-tumor and apoptotic effects in human HCC cells. Expand
Cyclooxygenase-2 inhibitors in colorectal cancer.
Results from initial clinical trials suggest that COX-2 inhibitors may be able to reduce the polyp burden in patients with familial polyposis coli and cause less toxic side effects compared with nonselective nonsteroidal anti-inflammatory drugs. Expand